 Martin Zamora
Concepts (273)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 31 | 2023 | 241 | 6.100 |
Why?
| | Cytomegalovirus Infections | 7 | 2012 | 175 | 1.780 |
Why?
| | Antiviral Agents | 12 | 2023 | 635 | 1.530 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2023 | 97 | 1.360 |
Why?
| | Lung Diseases | 7 | 2017 | 688 | 1.170 |
Why?
| | Postoperative Complications | 9 | 2015 | 2120 | 0.840 |
Why?
| | Bronchiolitis Obliterans | 7 | 2015 | 66 | 0.810 |
Why?
| | Ganciclovir | 5 | 2012 | 48 | 0.790 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 60 | 0.790 |
Why?
| | alpha 1-Antitrypsin Deficiency | 2 | 2018 | 69 | 0.600 |
Why?
| | Pneumonia, Viral | 1 | 2023 | 333 | 0.580 |
Why?
| | Graft Rejection | 9 | 2018 | 508 | 0.580 |
Why?
| | Heart Transplantation | 6 | 2016 | 652 | 0.570 |
Why?
| | Lung | 11 | 2017 | 3497 | 0.550 |
Why?
| | Pulmonary Medicine | 1 | 2017 | 69 | 0.550 |
Why?
| | Regeneration | 1 | 2017 | 158 | 0.510 |
Why?
| | Sirolimus | 3 | 2018 | 181 | 0.510 |
Why?
| | Diltiazem | 1 | 2014 | 23 | 0.460 |
Why?
| | Bronchial Arteries | 2 | 2010 | 11 | 0.440 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 528 | 0.410 |
Why?
| | Organ Transplantation | 3 | 2018 | 157 | 0.410 |
Why?
| | Transplant Recipients | 1 | 2014 | 130 | 0.410 |
Why?
| | Graft Survival | 5 | 2018 | 441 | 0.400 |
Why?
| | Pulmonary Circulation | 2 | 2010 | 400 | 0.380 |
Why?
| | Patient Selection | 6 | 2015 | 625 | 0.360 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 603 | 0.360 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 170 | 0.350 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2011 | 71 | 0.350 |
Why?
| | Transplantation, Homologous | 10 | 2018 | 373 | 0.350 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 349 | 0.340 |
Why?
| | Herpesviridae Infections | 1 | 2011 | 136 | 0.340 |
Why?
| | RNA Interference | 2 | 2013 | 426 | 0.330 |
Why?
| | Treatment Outcome | 10 | 2023 | 9006 | 0.320 |
Why?
| | Pulmonary Emphysema | 4 | 2015 | 265 | 0.320 |
Why?
| | Societies, Medical | 4 | 2018 | 654 | 0.320 |
Why?
| | Virus Diseases | 1 | 2011 | 192 | 0.320 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 320 | 0.290 |
Why?
| | Humans | 41 | 2023 | 113531 | 0.270 |
Why?
| | Cytomegalovirus | 2 | 2004 | 140 | 0.270 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2293 | 0.270 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2015 | 902 | 0.250 |
Why?
| | Capillaries | 1 | 2005 | 90 | 0.240 |
Why?
| | Autoantibodies | 2 | 2013 | 1349 | 0.240 |
Why?
| | Vasculitis | 1 | 2005 | 64 | 0.240 |
Why?
| | Immunosuppressive Agents | 4 | 2014 | 633 | 0.240 |
Why?
| | Drug Resistance, Viral | 3 | 2011 | 99 | 0.230 |
Why?
| | Waiting Lists | 3 | 2015 | 204 | 0.220 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2004 | 122 | 0.220 |
Why?
| | Reperfusion Injury | 3 | 2017 | 251 | 0.220 |
Why?
| | Risk Factors | 7 | 2013 | 8606 | 0.220 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2018 | 31 | 0.220 |
Why?
| | Pneumonectomy | 2 | 2018 | 118 | 0.210 |
Why?
| | Heart-Lung Transplantation | 2 | 2014 | 9 | 0.210 |
Why?
| | Consensus | 2 | 2016 | 533 | 0.210 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 662 | 0.190 |
Why?
| | Middle Aged | 14 | 2015 | 26552 | 0.170 |
Why?
| | Transplantation Tolerance | 1 | 2018 | 30 | 0.150 |
Why?
| | Endothelial Cells | 2 | 2013 | 677 | 0.150 |
Why?
| | Primary Graft Dysfunction | 2 | 2017 | 28 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2020 | 578 | 0.140 |
Why?
| | Adult | 9 | 2023 | 30245 | 0.140 |
Why?
| | Male | 18 | 2015 | 55112 | 0.140 |
Why?
| | Transplantation, Heterotopic | 2 | 2014 | 16 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 960 | 0.130 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 517 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2018 | 321 | 0.130 |
Why?
| | Frailty | 1 | 2018 | 112 | 0.130 |
Why?
| | DNA, Mitochondrial | 1 | 2017 | 181 | 0.130 |
Why?
| | Syndrome | 3 | 2015 | 328 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2017 | 194 | 0.130 |
Why?
| | Tissue Donors | 2 | 2016 | 313 | 0.130 |
Why?
| | Female | 17 | 2018 | 59115 | 0.120 |
Why?
| | International Cooperation | 1 | 2016 | 168 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 4384 | 0.120 |
Why?
| | Interleukin-18 | 2 | 2013 | 217 | 0.120 |
Why?
| | Fas Ligand Protein | 1 | 2014 | 55 | 0.120 |
Why?
| | Tissue and Organ Procurement | 2 | 2015 | 223 | 0.120 |
Why?
| | Asphyxia | 1 | 2014 | 21 | 0.120 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 12 | 0.110 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2015 | 238 | 0.110 |
Why?
| | Receptors, Steroid | 1 | 2014 | 45 | 0.110 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 38 | 0.110 |
Why?
| | Everolimus | 1 | 2014 | 61 | 0.110 |
Why?
| | Anastomosis, Surgical | 2 | 2013 | 131 | 0.110 |
Why?
| | Perfusion | 1 | 2014 | 147 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 61 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 2 | 2013 | 218 | 0.110 |
Why?
| | Health Resources | 1 | 2015 | 119 | 0.110 |
Why?
| | Tissue Distribution | 1 | 2014 | 280 | 0.110 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2014 | 49 | 0.110 |
Why?
| | CD146 Antigen | 1 | 2013 | 35 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 686 | 0.110 |
Why?
| | Demography | 1 | 2014 | 255 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1378 | 0.100 |
Why?
| | Animals | 12 | 2018 | 31162 | 0.100 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 1783 | 0.100 |
Why?
| | Immunocompromised Host | 2 | 2011 | 190 | 0.100 |
Why?
| | Vasodilator Agents | 1 | 2014 | 303 | 0.100 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 103 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2018 | 693 | 0.100 |
Why?
| | Injections, Intravenous | 1 | 2012 | 195 | 0.090 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 137 | 0.090 |
Why?
| | Cytokines | 2 | 2010 | 1795 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2015 | 1643 | 0.090 |
Why?
| | Viral Vaccines | 1 | 2011 | 87 | 0.090 |
Why?
| | Cell Communication | 1 | 2012 | 274 | 0.090 |
Why?
| | Length of Stay | 1 | 2015 | 963 | 0.090 |
Why?
| | Respiration, Artificial | 1 | 2014 | 536 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2012 | 432 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2010 | 57 | 0.090 |
Why?
| | Neprilysin | 1 | 2010 | 47 | 0.090 |
Why?
| | Gene Expression | 1 | 2014 | 1397 | 0.080 |
Why?
| | Preoperative Care | 1 | 2012 | 318 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2014 | 632 | 0.080 |
Why?
| | CD4 Antigens | 1 | 2010 | 123 | 0.080 |
Why?
| | Biomarkers | 3 | 2014 | 3389 | 0.080 |
Why?
| | Cost of Illness | 1 | 2011 | 255 | 0.080 |
Why?
| | Adoptive Transfer | 1 | 2010 | 194 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2010 | 154 | 0.080 |
Why?
| | Genotype | 1 | 2014 | 1733 | 0.080 |
Why?
| | Pulmonary Artery | 2 | 2012 | 1012 | 0.080 |
Why?
| | Pulmonary Fibrosis | 2 | 2013 | 321 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2010 | 633 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2010 | 407 | 0.080 |
Why?
| | Macrophages | 2 | 2013 | 1233 | 0.080 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 31 | 0.080 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 61 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2010 | 360 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 914 | 0.080 |
Why?
| | Recurrence | 1 | 2011 | 925 | 0.070 |
Why?
| | Macrophages, Alveolar | 2 | 2013 | 341 | 0.070 |
Why?
| | Body Temperature | 1 | 2008 | 176 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1822 | 0.070 |
Why?
| | Nurse Practitioners | 1 | 2008 | 95 | 0.070 |
Why?
| | Time Factors | 5 | 2015 | 6032 | 0.070 |
Why?
| | Fever | 1 | 2008 | 266 | 0.070 |
Why?
| | Trachea | 2 | 2007 | 220 | 0.070 |
Why?
| | Bacteremia | 1 | 2008 | 157 | 0.070 |
Why?
| | Terminology as Topic | 1 | 2007 | 185 | 0.070 |
Why?
| | Prognosis | 1 | 2014 | 3318 | 0.070 |
Why?
| | Aged | 7 | 2014 | 18944 | 0.060 |
Why?
| | Mice, Inbred BALB C | 3 | 2018 | 1136 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1176 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1236 | 0.060 |
Why?
| | Mice | 8 | 2014 | 14679 | 0.060 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2005 | 17 | 0.060 |
Why?
| | Tissue Transplantation | 1 | 2005 | 11 | 0.060 |
Why?
| | Calcineurin Inhibitors | 1 | 2005 | 57 | 0.060 |
Why?
| | CD40 Ligand | 1 | 2005 | 37 | 0.060 |
Why?
| | Rats | 4 | 2013 | 4829 | 0.060 |
Why?
| | Survival | 1 | 2004 | 37 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1725 | 0.060 |
Why?
| | Mice, Inbred C3H | 2 | 2018 | 242 | 0.060 |
Why?
| | Registries | 1 | 2012 | 1762 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2004 | 141 | 0.060 |
Why?
| | Hypoxia | 1 | 2010 | 919 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 4400 | 0.060 |
Why?
| | Drug Resistance | 1 | 2004 | 158 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2013 | 2139 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 712 | 0.050 |
Why?
| | Quality Assurance, Health Care | 1 | 2005 | 309 | 0.050 |
Why?
| | Torsion Abnormality | 1 | 2003 | 18 | 0.050 |
Why?
| | Respiratory Mucosa | 1 | 2005 | 251 | 0.050 |
Why?
| | Capillary Permeability | 2 | 2013 | 134 | 0.050 |
Why?
| | Prevalence | 1 | 2009 | 2244 | 0.050 |
Why?
| | Fibrosis | 1 | 2005 | 452 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2310 | 0.050 |
Why?
| | Young Adult | 3 | 2014 | 10400 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 4617 | 0.050 |
Why?
| | Genomics | 1 | 2006 | 625 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2018 | 1925 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 984 | 0.050 |
Why?
| | Neutrophils | 1 | 2006 | 1072 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 829 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2013 | 2523 | 0.040 |
Why?
| | Prospective Studies | 1 | 2012 | 6189 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 33 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 85 | 0.040 |
Why?
| | Adolescent | 4 | 2014 | 17724 | 0.040 |
Why?
| | Transplantation Immunology | 2 | 2013 | 30 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2013 | 2993 | 0.040 |
Why?
| | Early Diagnosis | 2 | 2013 | 218 | 0.040 |
Why?
| | Ribavirin | 1 | 2020 | 89 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2013 | 394 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2015 | 12504 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2018 | 45 | 0.040 |
Why?
| | CD28 Antigens | 1 | 2018 | 47 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1604 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1510 | 0.040 |
Why?
| | Cyclosporine | 1 | 2018 | 160 | 0.040 |
Why?
| | Cell Line | 2 | 2013 | 2581 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 182 | 0.030 |
Why?
| | Acute Disease | 2 | 2010 | 885 | 0.030 |
Why?
| | Isoantibodies | 1 | 2016 | 45 | 0.030 |
Why?
| | Cell Movement | 2 | 2012 | 852 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 345 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 516 | 0.030 |
Why?
| | Genes, RAG-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1032 | 0.030 |
Why?
| | Tidal Volume | 1 | 2014 | 73 | 0.030 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 67 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1682 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.030 |
Why?
| | Patient Admission | 1 | 2015 | 175 | 0.030 |
Why?
| | Gene Deletion | 1 | 2014 | 351 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 2013 | 98 | 0.030 |
Why?
| | Aorta, Abdominal | 1 | 2013 | 38 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 67 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2018 | 716 | 0.030 |
Why?
| | Neck | 1 | 2013 | 84 | 0.030 |
Why?
| | Child | 1 | 2011 | 18340 | 0.030 |
Why?
| | Abdomen | 1 | 2013 | 99 | 0.030 |
Why?
| | Inhalation Exposure | 1 | 2013 | 95 | 0.030 |
Why?
| | History, 21st Century | 1 | 2013 | 158 | 0.020 |
Why?
| | Rats, Nude | 1 | 2012 | 26 | 0.020 |
Why?
| | Cardiomegaly | 1 | 2013 | 158 | 0.020 |
Why?
| | Tobacco Products | 1 | 2013 | 96 | 0.020 |
Why?
| | Fluoresceins | 1 | 2012 | 45 | 0.020 |
Why?
| | History, 20th Century | 1 | 2013 | 265 | 0.020 |
Why?
| | Cell Death | 1 | 2013 | 320 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 344 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2012 | 190 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1634 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 842 | 0.020 |
Why?
| | United States | 2 | 2018 | 12137 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 447 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 248 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 496 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 297 | 0.020 |
Why?
| | H-2 Antigens | 1 | 2010 | 110 | 0.020 |
Why?
| | Myocardium | 1 | 2014 | 906 | 0.020 |
Why?
| | Oximetry | 1 | 2010 | 80 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2010 | 193 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 770 | 0.020 |
Why?
| | Weight Loss | 1 | 2013 | 640 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2008 | 109 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 508 | 0.020 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2008 | 71 | 0.020 |
Why?
| | International Agencies | 1 | 2007 | 29 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 22 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1128 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2010 | 369 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 130 | 0.020 |
Why?
| | Decompression, Surgical | 1 | 2008 | 92 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2008 | 185 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1004 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 180 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 127 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 3802 | 0.020 |
Why?
| | Reoperation | 1 | 2008 | 505 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 827 | 0.020 |
Why?
| | Eosinophilia | 1 | 2007 | 186 | 0.020 |
Why?
| | Inpatients | 1 | 2008 | 379 | 0.020 |
Why?
| | Transplantation Chimera | 1 | 2005 | 50 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 1589 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2012 | 2164 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 357 | 0.010 |
Why?
| | Biopsy | 1 | 2007 | 1024 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 739 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3470 | 0.010 |
Why?
| | Respiratory System | 1 | 2005 | 137 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1328 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1528 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 4593 | 0.010 |
Why?
| | Pneumonia | 1 | 2007 | 561 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2752 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1570 | 0.010 |
Why?
| | Immunotherapy | 1 | 2005 | 472 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1733 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2269 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2004 | 1282 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 2507 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2444 | 0.010 |
Why?
|
|
Zamora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|